TC
IDXX icon

Trium Capital’s Idexx Laboratories IDXX Stock Holding History

Trium Capital’s Portfolio IDXX Stock Details IDXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-4,111
Closed -$1.8K – 74
2023
Q3 		$1.8K Hold
4,111
– – 0.03% 38
2023
Q2 		$2.06K Buy
4,111
+1,691
+70% +$810K 0.44% 41
2023
Q1 		$1.21M Buy
2,420
+92
+4% +$44K 0.42% 49
2022
Q4 		$950K Buy
+2,328
New +$904K 0.35% 56

Other funds holding IDXX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Trium Capital's IDXX Position: Q4 2023 in Review

Trium Capital sold out of Idexx Laboratories (IDXX) in Q4 2023, closing a stake of 4,111 shares — an estimated $1.8K sold.

Trium Capital first reported a position in IDXX in Q4 2022 and held it in 4 quarters. The position peaked at $1.21M in Q1 2023. 1,153 funds tracked by Wall St. Rank hold IDXX as of Q4 2023.

  • Trium Capital reported no remaining Idexx Laboratories position as of Q4 2023 after selling out during the quarter.
  • Trium Capital sold 4,111 Idexx Laboratories shares in Q4 2023, an estimated $1.8K.
  • Trium Capital first reported a position in Idexx Laboratories in Q4 2022 and held it in 4 quarters.
  • Trium Capital's Idexx Laboratories position peaked at $1.21M in Q1 2023.
  • 1,153 funds tracked by Wall St. Rank held Idexx Laboratories as of Q4 2023.

Based on Trium Capital's 13F filing for Q4 2023, filed 9 Feb 2024.